(Q36837144)

16 August 2017

1 reference

title

Virus-like particles: flexible platforms for vaccine development (English)

1 reference

16 August 2017

1 reference

1

Bryce Chackerian

1 reference

16 August 2017

1 June 2007

1 reference

Expert Review of Vaccines

16 August 2017

1 reference

16 August 2017

6

1 reference

16 August 2017

3

1 reference

16 August 2017

381-390

1 reference

Oral immunogenicity of human papillomavirus-like particles expressed in potato

16 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Efficient intracellular assembly of papillomaviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Virus-like particles: passport to immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Neutralizing antiviral B cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Polyvalent antigens stabilize B cell antigen receptor surface signaling microdomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Molecular determinants of immunogenicity: the immunon model of immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Role of B cells in antigen presentation of the hepatitis B core

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

HPV6b virus like particles are potent immunogens without adjuvant in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

A new foreign policy: MHC class I molecules monitor the outside world

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Yeast-derived human immunodeficiency virus type 1 p55(gag) virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8(+) T cells by cross-presentation of DCs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Ebola and Marburg virus-like particles activate human myeloid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

New tools for antigen delivery to the MHC class I pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

A universal influenza A vaccine based on the extracellular domain of the M2 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Combinatorial approach to hepadnavirus-like particle vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Natural supramolecular building blocks. Cysteine-added mutants of cowpea mosaic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

A Viral Platform for Chemical Modification and Multivalent Display

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Antibodies as therapeutic agents: vive la renaissance!

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Immunogenicity of engineered antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Receptor editing in self-reactive bone marrow B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Receptor editing: an approach by autoreactive B cells to escape tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Predominant autoantibody production by early human B cell precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Therapeutic vaccination to block receptor-ligand interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Determinants of autoantibody induction by conjugated papillomavirus virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Therapeutic vaccination for chronic diseases: a new class of drugs in sight

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Recombinant parvovirus-like particles as an antigen carrier: a novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

A second vaccine revolution for the new epidemics of the 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

The hepatitis nucleocapsid as a vaccine carrier moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

HBV core particles as a carrier for B cell/T cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Parvovirus B19 empty capsids as antigen carriers for presentation of antigenic determinants of dengue 2 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

A chimaeric plant virus vaccine protects mice against a bacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Modified tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Hybrid Ty virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.3.381

21 January 2018

Identifiers

DOI

10.1586/14760584.6.3.381

1 reference

16 August 2017

1 reference

PubMed ID

17542753